A5062144298- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Liver Disease and Transplantation
- Inflammatory Biomarkers in Disease Prognosis
- Cancer, Stress, Anesthesia, and Immune Response
- Circular RNAs in diseases
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Immunotherapy and Immune Responses
- Ovarian cancer diagnosis and treatment
- Peptidase Inhibition and Analysis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer-related molecular mechanisms research
- Cancer, Lipids, and Metabolism
- Neuroendocrine Tumor Research Advances
- MicroRNA in disease regulation
- CAR-T cell therapy research
- Advanced Breast Cancer Therapies
- Protease and Inhibitor Mechanisms
- Lung Cancer Treatments and Mutations
- Cancer Mechanisms and Therapy
- Extracellular vesicles in disease
- Glioma Diagnosis and Treatment
Beijing Ditan Hospital
2021-2022
Capital Medical University
2021-2022
Background: Hepatocellular carcinoma (HCC) accounts for the majority of liver cancer, with incidence and mortality rates increasing every year. Despite improvement clinical management, substantial challenges remain due to its high recurrence short survival period. This study aimed identify potential diagnostic prognostic biomarkers in HCC through bioinformatic analysis. Methods: Datasets from GEO TCGA databases were used Gene Ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) enrichment...
Background. The presence of a capsule is an important prognostic factor in hepatocellular carcinoma (HCC). Capsule formation affected by tumor-host interaction, which may include collagen deposition and extracellular matrix (ECM) degradation. Purpose. This study aimed to examine whether single-nucleotide polymorphisms (SNPs) the genes for COL1A1 MUC15, MMP14, CD97, SMYD3, BRAF, transforming growth beta 1 (TGF-β) are related formation. Methods. We prospectively recruited analyzed 185 patients...
Advanced hepatocellular carcinoma (HCC) is characterized as symptomatic tumors [performance status (PS) score of 1-2], vascular invasion and extrahepatic spread, but patients with PS1 alone may be eliminated from this stage. Although liver resection used for liver-confined HCC, its role in remains controversial. Therefore, we aimed to explore application such identify potential candidates. Eligible HCC undergoing were retrospectively screened 15 Chinese tertiary hospitals, limited tumor...